Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content
COVID-10 GPH

COVID-19 GPH|Home|PHGKB Last data update: Mar 28, 2023 . (Total: 44687 Documents since 2020)
   dataset      

Last Posted: Mar-28-2023 06:33:20
spot light Spotlight

Determinants of COVID-19 vaccine fatigue.
Tanja A Stamm et al. Nature medicine 2023 3

Our results suggest that vaccination campaigns should be tailored to subgroups based on their vaccination status. Among the unvaccinated, campaign messages conveying community spirit had a positive effect (0.343, confidence interval (CI) 0.019–0.666), whereas offering positive incentives, such as a cash reward (0.722, CI 0.429–1.014) or voucher (0.670, CI 0.373–0.967), was pivotal to the decision-making of those vaccinated once or twice. Among the triple vaccinated, vaccination readiness increased when adapted vaccines were offered (0.279, CI 0.182–0.377), but costs (-0.795, CI -0.935 to -0.654) and medical dissensus (-0.161, CI -0.293 to -0.030) reduced their likelihood to get vaccinated.

Rare Primary Immunodeficiency Diseases and COVID-19: Evolving Insights and Implications for Clinical and Public Health Practice
E Drzymalla et al, CDC Blog Post, March 27, 2023

We explore how new research on rare genetic diseases is contributing to our understanding of COVID-19 occurrence and outcomes and discuss potential clinical and public health implications. Understanding the mechanisms involved in these inherited disorders may shed light on biological mechanisms and natural history of COVID-19. Although only a small proportion of patients are ill due to rare, single gene disorders, studying them may improve understanding of underlying biological pathways, eventually leading to new therapies that are relevant across the disease spectrum.

Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis.
Deborah Cromer et al. Nature communications 2023 3 (1) 1633

We find that predicted neutralising antibody titres are strongly correlated with observed vaccine effectiveness against symptomatic (Spearman [Formula: see text] = 0.95, p < 0.001) and severe (Spearman [Formula: see text] = 0.72, p < 0.001 for both) COVID-19 and that the loss of neutralising antibodies over time and to new variants are strongly predictive of observed vaccine protection against severe COVID-19.

People who catch Omicron are less likely to get Long Covid Vaccination, virus biology may be driving down risk
J Couzin-Frankel, Science, March 2023

After Omicron began spreading in late 2021, COVID-19 deaths became a rarity even among frail and immunocompromised patients, he says. And infections now carry a lower threat of lingering complications. “These patients with Omicron, they’re much less likely to get Long Covid,” says Willan, whose patients are overwhelmingly vaccinated. Earlier this month, he reported in the British Journal of Haematology that his patients’ risk of Long Covid symptoms 3 months after infection had dropped from 46% with the original coronavirus strain and another called Alpha, to 35% with the Delta variant, to 14% with Omicron.


news Latest News and Publications
Comparison of SARS-CoV-2 diagnosis by rapid antigen detection kit with RT-qPCR in a tertiary care setup in North Eastern India.
Majumder Saikat, et al. Indian journal of medical microbiology 2023 0 0. 12-16

New Added Today


Impact of public health and social measures on contact dynamics during a SARS-CoV-2 Omicron variant outbreak in Quanzhou, China, March to April 2022.
Guo Yichao, et al. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2023 0 0.

New Added Today


SARSCoV2 Omicron (B. 1.1. 529) recent updates and challenges worldwide.
Das Rina, et al. Infectious disorders drug targets 2023 0 0.

New Added Today


Corrigendum: Elevated IFNA1 and suppressed IL12p40 associated with persistent hyperinflammation in COVID-19 pneumonia.
Jeon Kyeongseok, et al. Frontiers in immunology 2023 0 0. 1175767

New Added Today


Editorial: SARS-COV-2 infections within inborn errors of immunity populations.
Hanitsch Leif Gunnar, et al. Frontiers in immunology 2023 0 0. 1164045

New Added Today


IgG3 Antibody Response to COVID-19 Vaccination in a Patient With a Large Heavy Chain Deletion.
Sarkaria Sandeep, et al. Therapeutic advances in allergy and rhinology 2023 0 0. 27534030231156206

New Added Today


All Latest

About COVID-19 GPH

COVID-19 GPH is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that capture emerging discoveries and applications of genomics, molecular and other precision medicine and precision public health tools in the investigation and control of COVID-19. Contents include PubMed records via an automated pubmed search algorithm, preprint records from NIH iCite, the relevant information from many media sources picked by experts, and linkages to contents from our curated PHGKB databases.

Site Citation:
Wei Yu, et al. COVID-19 GPH: tracking the contribution of genomics and precision health to the COVID-19 pandemic response. BMC Infectious Diseases (2022) 22:402.

update trend

Sign up Email Alert

Summary

All Records44687
Genomics Precision Health32671
Non-Genomics Precision Health12016

Publication Categories Brand

Variants 13262
Vaccines 11184
Treatment 10520
Mechanism 10352
Diagnosis 7643
Prevention 5345
Surveillance 3944
Forecasting 3494
Transmission 2145
Health Equity 1146

Publication Types

PubMed Records34221
Preprints10020
Online News/Reports/Publications433

Genomics Precision Health (GPH): The use of pathogen and human genomics and advanced molecular detection methods in discovery, clinical and public health investigations and response to COVID-19.
Non Genomics Precision Health (non-GPH): The use of big data, data science, digital health, machine learning and predictive analytic methods (not involving genomics) in discovery, clinical and public health investigations and response to COVID-19


Following categories are annotated by LitCovid from NCBI NIH.
MechanismUnderlying cause(s) of covid-19 infections and transmission & possible drug mechanism of action
Transmission Characteristics and modes of covid-19 transmissions, such as human-to-human
DiagnosisDisease assessment through symptoms, test results, and radiological features
PreventionPrevention, control, response and management strategies
Case ReportDescriptions of specific patient cases
ForecastingModelling and estimating the trend of covid-19 spread

Following categories are annotated by the text mining tool from CDC PHGKB
Health EquityRelevant to health equity. Search terms are derived from a list provided by the Association for Territorial Health Officials which include terms such as diversity, health disparities, and others.
VaccineRelevant to vaccine development, evaluation, implementation and impact. For additional information on vaccines and COVID-19. Check out general CDC Information pages
VariantRelevant to SARS-CoV-2 variants and their impact on public health. For additional information on variants COVID-19. Check out CDC New Variants of the Virus that Causes COVID-19 page
SurveillanceRelevant to SARS-CoV-2 public health surveillance and tracking. For additional information on COVID-19 surveillance, check out CDC COVID-19 Data Tracker

Disclaimer: Articles listed in the Public Health Genomics and Precision Health Knowledge Base are selected by the CDC Office of Genomics and Precision Public Health to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

TOP